Agnieszka Karbownik

Poznan University of Medical Sciences — Poland

Pharmacology, Toxicology and Pharmaceutics · Life Sciences

10h-index330citations51works2.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Pharmacogenetics and Drug Metabolism(11), Drug Transport and Resistance Mechanisms(8), Metabolism, Diabetes, and Cancer(7), Drug-Induced Hepatotoxicity and Protection(7), Antibiotics Pharmacokinetics and Efficacy(5)

Publications51 total

Development of a UPLC-MS/MS method and its application for the pharmacokinetic analysis of regorafenib in rats
Scientific Reports·2026Open Access
Niraparib induces hyperglycemia in ovarian cancer patients: a preliminary pilot study
Pharmacological Reports·2025Open Access
Microbial Crosstalk with Therapy: Pharmacomicrobiomics in AML—One Step Closer to Personalized Medicine
Biomedicines·2025· 2 citedOpen Access
Niraparib induces hyperglycaemia in ovarian cancer patients - is there any influence of BMI?
2025Open Access
Analysis of niraparib-induced changes in glucose levels during three-month therapy in normoglycemic patients with ovarian cancer.
Journal of Clinical Oncology·2025· 2 cited
Effect of hypoalbuminemia on drug pharmacokinetics
Frontiers in Pharmacology·2025· 16 citedOpen Access
Pharmacokinetic Interaction Between Olaparib and Regorafenib in an Animal Model
Pharmaceutics·2024Open Access
A Pharmacokinetic Study of the Interaction Between Regorafenib and Paracetamol in Male Rats
Pharmaceutics·2024· 3 citedOpen Access
Bioanalytical method validation for therapeutic drug monitoring of olaparib in patients with ovarian cancer
Acta Poloniae Pharmaceutica - Drug Research·2024Open Access
Pharmacokinetic interaction between regorafenib and atorvastatin in rats
Pharmacological Reports·2024· 6 citedOpen Access
Successful examples of asynchronous teaching in Polish interactive remote medical education
International Journal of Research in E-learning·2023· 1 citedOpen Access
Bidirectional pharmacokinetic drug interactions between olaparib and metformin
Cancer Chemotherapy and Pharmacology·2023· 9 citedOpen Access
Midostaurin – the First Targeted Therapy Drug for Patients with Acute Myeloid Leukaemia with FLT3 Mutation
Acta Poloniae Pharmaceutica - Drug Research·2023· 1 citedOpen Access
The metabolic conversion of metamizole (Dipyrone) in male and female patients after total gastrectomy for stomach cancer.
Acta Poloniae Pharmaceutica - Drug Research·2022· 1 citedOpen Access
Pharmacokinetic Drug Interaction Study of Sorafenib and Morphine in Rats
Pharmaceutics·2021· 10 citedOpen Access
Correction to: The oxidation and hypoglycaemic effect of sorafenib in streptozotocin-induced diabetic rats
Pharmacological Reports·2021Open Access
The Influence of Paracetamol on the Penetration of Sorafenib and Sorafenib N-Oxide Through the Blood–Brain Barrier in Rats
European Journal of Drug Metabolism and Pharmacokinetics·2020· 6 citedOpen Access
In vivo assessment of potential for UGT-inhibition-based drug-drug interaction between sorafenib and tapentadol
Biomedicine & Pharmacotherapy·2020· 11 citedOpen Access
Pharmacokinetic Interaction between Sorafenib and Atorvastatin, and Sorafenib and Metformin in Rats
Pharmaceutics·2020· 19 citedOpen Access
In vivo assessment of the drug interaction between sorafenib and paracetamol in rats
Cancer Chemotherapy and Pharmacology·2020· 9 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Edyta Szałek(46), Edmund Grześkowiak(38), Tomasz Grabowski(32), Anna Wolc(29), Katarzyna Sobańska(16), Joanna Stanisławiak‐Rudowicz(13), Hanna Urjasz(8), Wojciech Połom(7), Marcin Matuszewski(7), Joanna Porażka(7), Danuta Szkutnik-Fiedler(6), Konrad Lewandowski(5), Włodzimierz Płotek(4), Andrzej Czyrski(4), Filip Otto(4), Dawid Murawa(4), Anna Stachowiak(4), Agnieszka Klupczyńska(3), Szymon Plewa(3), Franciszek K. Główka(3)